相关实验视频

Updated: Aug 24, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

在可切除的黑色素瘤中使用新辅助剂relatilimab和nivolumab

Rodabe N Amaria¹, Michael Postow², Elizabeth M Burton³

¹Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rnamaria@mdanderson.org.

|October 26, 2022

概括

在可切除的黑色素瘤患者中,relatlimab和nivolumab免疫疗法的组合显示出高的病理完整响应率. 这种新辅助疗法显示出有前途的安全性和有效性,改善了无复发的生存率.

科学领域:

癌症学
免疫疗法
黑色素瘤研究

背景情况:

在不可切除的晚期黑色素瘤中,relatlimab加nivolumab组合免疫疗法改善了无进展的存活率.
这种组合在切除性黑色素瘤的新辅助环境中的有效性和安全性以前尚未研究.

研究的目的:

在可切除的临床III阶段或小细胞扩散性IV阶段黑色素瘤患者中研究新辅助剂relatlimab和nivolumab组合免疫治疗的疗效和安全性.
评估病理完整反应 (pCR) 率作为主要终点.

主要方法:

患者每4周接受两次新辅助剂量尼沃卢马布 (480毫克) 和相关剂量 (160毫克),然后进行手术.
辅助组合治疗包括手术后的十次剂量.
评估了固体瘤的病理完整反应 (pCR) 率和反应评估标准 (RECIST 1. 1).

主要成果:

在30名患者中,组合治疗实现了57%的PCR率和70%的整体病理反应率.
在新辅助治疗中,放射性反应率为57%,没有3 - 4级免疫相关的不良事件.
有任何病理反应的患者的1年和2年无复发生存率分别为100%和92%,明显高于没有病理反应的患者.

结论:

在可切除的黑色素瘤中,新辅助剂relatlimab和nivolumab组合免疫疗法会诱导高PCR率.
与其他组合免疫疗法相比,该疗法在新辅助疗法期间具有良好的安全性.
这些发现以及RELATIVITY-047试验证实了这种免疫治疗方案的有效性和安全性.

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...